文献速递眼底病与葡萄膜炎

阿达木单抗与英夫利西单抗生物类似药转换治疗非感染性葡萄膜炎的临床疗效:系统综述与Meta分析

Clinical Efficacy of Biosimilar Switch of Adalimumab and Infliximab for Noninfectious Uveitis: Systematic Review and Meta-Analysis.
PubMed 文献 · Am J Ophthalmol · 2025-11-19

该系统综述与Meta分析纳入6项研究共202例由原研TNF-α抑制剂转换为生物类似药的非感染性葡萄膜炎患者,转换后葡萄膜炎发作的合并IRR为1.26(95%CI 0.72-2.21,P=0.411),口服糖皮质激素使用风险(RR=1.00)及非生物免疫调节治疗使用风险(RR=0.98)均无显著变化;30例患者(合并比例0.10)换回原研药,多因注射部位疼痛或生物类似药注射器技术困难。作者认为转换未伴随发作率增加,支持临床等效性,但部分患者可能出现耐受性问题或早期发作,需在转换后数月内密切监测。

要点

  • 202例非感染性葡萄膜炎患者由原研TNF-α抑制剂转换为生物类似药后,葡萄膜炎发作合并IRR为1.26(95%CI 0.72-2.21),未达统计学显著。
  • 转换后口服糖皮质激素使用风险(RR=1.00,95%CI 0.88-1.12)和非生物免疫调节治疗使用风险(RR=0.98,95%CI 0.83-1.16)均无显著变化。
  • 30例患者(合并比例0.10,95%CI 0.041-0.219)换回原研药,最常见原因为注射部位疼痛或生物类似药注射器技术困难。

核心结论

  • 非感染性葡萄膜炎患者由原研TNF-α抑制剂转换为生物类似药未伴随葡萄膜炎发作率增加,支持这些生物类似药的临床等效性。
  • 部分患者可能出现耐受性问题或早期发作,作者认为需在转换后数月内密切监测。

研究设计与样本

  • 系统综述与Meta分析,遵循PRISMA指南并在PROSPERO注册(ID:CRD420251051301),检索PubMed、Embase和Scopus。
  • 纳入报告转换前后葡萄膜炎控制结局(发作频率、口服糖皮质激素使用或非生物免疫调节治疗使用)的研究,共纳入6项研究、202例由原研药转换为生物类似药的患者,发表年份为2019年至2024年。

主要发现

  • 转换后葡萄膜炎发作的合并IRR为1.26(95%CI 0.72-2.21,P=0.411),存在显著异质性(P=0.08)。
  • 排除转换后3个月内发生的发作进行二次分析(因1项研究报告早期发作聚集),IRR为1.20(95%CI 0.79-1.83,P=0.388),无异质性(P=.25)。
  • 转换后口服糖皮质激素使用风险无显著变化(RR=1.00,95%CI 0.88-1.12,P=0.944)。
  • 转换后非生物免疫调节治疗使用风险无显著变化(RR=0.98,95%CI 0.83-1.16,P=.858)。
  • 30例患者换回原研药(合并比例0.10,95%CI 0.041-0.219,P=0.022),最常见原因为注射部位疼痛或生物类似药注射器技术困难。

临床怎么用

  • 作者认为非感染性葡萄膜炎由原研TNF-α抑制剂转换为生物类似药未伴随发作率增加,支持临床等效性。
  • 作者认为部分患者可能出现耐受性问题或早期发作,需在转换后数月内密切监测。

局限性

  • 转换后葡萄膜炎发作合并IRR存在显著异质性(P=0.08)。
  • 作者结论指出部分患者可能出现耐受性问题或早期发作,需在转换后数月内密切监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the clinical efficacy of switching from originator tumor necrosis factor-alpha (TNF-α) inhibitors to biosimilars in the management of noninfectious uveitis. DESIGN: A systematic review and meta-analysis. METHODS: A systematic review and meta-analysis were conducted on PubMed, Embase, and Scopus according to PRISMA guidelines and registered on PROSPERO (ID: CRD420251051301). Studies were included if they reported outcomes related to uveitis control, including flare frequency, oral corticosteroid use, or nonbiologic immunomodulatory therapy (IMT) use, before and after switching. Meta-analyses were performed to compare the incidence rate ratio (IRR) of uveitis flares, as well as the risk ratios (RR) of oral corticosteroid and nonbiological IMT use, before and after switching. RESULTS: A total of 6 studies were included, with publication dates ranging from 2019 to 2024. The studies included a total of 202 patients that underwent an originator to biosimilar switch. The pooled IRR of uveitis flares postswitch was 1.26 (95% CI: 0.72-2.21, P = 0.411), with significant heterogeneity (P = 0.08). Heterogeneity could be resolved through a secondary analysis excluding flares occurring within 3 months postswitch, due to early flare clustering reported in 1 study, that found an IRR of 1.20 (95% CI: 0.79-1.83, P = 0.388) without heterogeneity (P = .25). There was no significant change in the risk of oral steroid use (RR = 1.00; 95% CI: 0.88-1.12, P = 0.944) or nonbiologic IMT use (RR = 0.98; 95% CI 0.83-1.16, P = .858) postswitch. A total of 30 patients (Pooled Proportions = 0.10; 95% CI: 0.041-0.219, P = 0.022) reverted to the originator agent, most commonly due to injection-site pain or technical difficulties with the biosimilar injector. CONCLUSIONS: Switching from originator to biosimilar TNF-α inhibitors in noninfectious uveitis was not associated with an increase in flare rates, supporting the clinical equivalence of these biosimilars. However, a subset of patients may experience tolerability issues or early flares, warranting close monitoring in the months following a switch.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Zhang C, Ayoubi M, Aboukasm G, et al. Clinical Efficacy of Biosimilar Switch of Adalimumab and Infliximab for Noninfectious Uveitis: Systematic Review and Meta-Analysis. Am J Ophthalmol. 2025. PMID: 41265720. doi:10.1016/j.ajo.2025.11.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。